2025 United Kingdom Acute Migraine Drugs Market Revenue Opportunities Report
Description
The 2025 United Kingdom Acute Migraine Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Acute Migraine Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the acute migraine drugs market in the United Kingdom are Pfizer Inc., Teva Pharmaceutical, Eli Lilly and Company, and GlaxoSmithKline (GSK). Pfizer is notable for its development and marketing of migraine treatments such as Rimegepant, a CGRP receptor antagonist approved by the EMA for migraine relief. Teva Pharmaceutical offers migraine therapies including AJOVY® (fremanezumab), focusing on expanding indications and delivery methods. Eli Lilly distributes key migraine medications like Emgality (galcanezumab) and RAYVOW (lasmiditan) in Europe, including the UK, through agreements with other global firms. GlaxoSmithKline (GSK), a major UK-based pharmaceutical, is recognized for its active role in migraine drug development and commercialization within the UK market.
These companies lead market innovation and capture significant market shares by focusing on novel drug formulations, expanding approvals for acute and preventive migraine treatments, and leveraging distribution partnerships. For example, Pfizer recently received FDA approval for Zavzpret, a nasal spray CGRP antagonist for acute migraine. Teva Pharmaceutical holds patents for novel delivery technologies enhancing patient convenience. Eli Lilly’s partnership with Organon strengthens its European footprint, and GSK’s extensive UK presence ensures strong market engagement. Together, these companies drive growth in the UK acute migraine drugs segment amid rising demand for effective, fast-acting migraine therapies.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Acute Migraine Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the acute migraine drugs market in the United Kingdom are Pfizer Inc., Teva Pharmaceutical, Eli Lilly and Company, and GlaxoSmithKline (GSK). Pfizer is notable for its development and marketing of migraine treatments such as Rimegepant, a CGRP receptor antagonist approved by the EMA for migraine relief. Teva Pharmaceutical offers migraine therapies including AJOVY® (fremanezumab), focusing on expanding indications and delivery methods. Eli Lilly distributes key migraine medications like Emgality (galcanezumab) and RAYVOW (lasmiditan) in Europe, including the UK, through agreements with other global firms. GlaxoSmithKline (GSK), a major UK-based pharmaceutical, is recognized for its active role in migraine drug development and commercialization within the UK market.
These companies lead market innovation and capture significant market shares by focusing on novel drug formulations, expanding approvals for acute and preventive migraine treatments, and leveraging distribution partnerships. For example, Pfizer recently received FDA approval for Zavzpret, a nasal spray CGRP antagonist for acute migraine. Teva Pharmaceutical holds patents for novel delivery technologies enhancing patient convenience. Eli Lilly’s partnership with Organon strengthens its European footprint, and GSK’s extensive UK presence ensures strong market engagement. Together, these companies drive growth in the UK acute migraine drugs segment amid rising demand for effective, fast-acting migraine therapies.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
